ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0677

Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan

SOKO KAWASHIMA1, Yoshinori Komagata1, Mitsumasa Kishimoto2 and Shinya Kaname1, 1Kyorin University School of Medicine, Tokyo, Japan, 2Kyorin University School of Medicine, Yokohoma, Japan

Meeting: ACR Convergence 2023

Keywords: ANCA associated vasculitis, Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss), Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab (MPZ) are different in Asian countries. In addition, there have been few reports on the course of long-term treatment of EGPA with MPZ. We conducted a retrospective analysis of the clinical database of the 25 patients of EGPA treated with MPZ in our hospital for remission induction or remission maintenance.

Methods: Twenty-five EGPA patients [19 females and 6 males. 11 MPO-ANCA positive and 14 MPO-negative.] have been treated with MPZ and followed for at least two years since 2018 in the department of Nephrology and Rheumatology in Kyorin University Hospital. They were analysed for clinical courses, including dose of administered corticosteroids (GC) and rates of flare-up. Remission was defined as Birmingham Vasculitis Activity Score (BVAS) was 0. Disease flare-up was defined as a state the disease activity increased and required intensification of immunosuppressive therapy.

They were divided into patients who were administered MPZ within 3 months of onset (early administration group) and who were started administration of MPZ during maintenance therapy at least 3 months after onset (during maintenance group).

Results: Of the 25 patients administered MPZ, 6 patients were categorized as the early administration group (1 male and 5 females; 4 patients were ANCA-positive and 2 patients were ANCA-negative) and the other 19 patients were categorized as the during maintenance group (5 males and 14 females; 7 patients were ANCA-positive and 12 patients were ANCA-negative). Mean ages at onset of groups of the early administration and the during maintenance were 52.2 and 55.0 years old, respectively.

In addition to GC and MPZ, cyclophosphamide (CY) was used in 17% (1/6) of the early group and in 53% (10/19) of the maintenance group.

After two years of therapy, mean doses of GC of each group were 1.7±2.1mg/day and 3.6±2.7mg/day, respectively. The achievement rates of GC dose below 5mg/day after two years treatment of the early group and the maintenance group were 100% and 47% (9/19), respectively. While no flare-up was observed in the early group, 26% (5/19) of the maintenance group developed flare-up after the start of MPZ therapy. These results were similar regardless of ANCA positivity. The incidence of serious infections requiring hospitalization and death after starting MPZ were 0 in both groups.

Conclusion: These results showed that long-term use of MPZ was effective and had an acceptable safety profile in EGPA patients. The use of MPZ from early stage might be recommended because the start of MPZ within 3 months of onset might reduce the dose of GCs after two years of therapy and the flare-up rate.


Disclosures: S. KAWASHIMA: None; Y. Komagata: None; M. Kishimoto: AbbVie, 2, 6, Amgen, 2, 6, Asahi-Kasei Pharma, 2, 6, Astellas, 2, 6, Ayumi Pharma, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Celgene, 2, 6, Chugai, 2, 6, Daiichi-Sankyo, 2, 6, Eisai, 2, 6, Eli Lilly, 2, 6, Gilead, 2, 6, Janssen, 2, 6, Novartis, 2, 6, Ono Pharma, 2, 6, Pfizer, 2, 6, Tanabe-Mitsubishi, 2, 6, UCB, 2, 6; S. Kaname: None.

To cite this abstract in AMA style:

KAWASHIMA S, Komagata Y, Kishimoto M, Kaname S. Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/analysis-of-clinical-outcomes-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-treated-with-mepolizumab-over-2-years-for-remission-induction-or-maintenance-a-single-center-experience-in-japan/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-clinical-outcomes-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-treated-with-mepolizumab-over-2-years-for-remission-induction-or-maintenance-a-single-center-experience-in-japan/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology